Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Sickle-Cell Anemia

Sickle-Cell Anemia

Part of Anemia

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Sickle-Cell Anemia

34 trials tracked for Sickle-Cell Anemia: 7 in phase 3 or 4 and 4 with published results. The most-cited published study has 789 citations.

34Trials tracked
7Phase 3 & 4
0Recruiting
4With published results
Phase distribution
Phase 4 2 Phase 3 5 Phase 2 15 Phase 1 3 Other / NA 9
  1. Phase 3 Hydroxyurea to Prevent Organ Damage in Children With Sickle Cell Anemia Completed · 789 cited
  2. Phase 3 A Phase III Safety and Efficacy Study of L-Glutamine to Treat Sickle Cell Disease or Sickle βo-thalassemia Completed · 543 cited
  3. Phase 3 Novel Use Of Hydroxyurea in an African Region With Malaria Completed · 150 cited
  4. Phase 3 Efficacy and Safety of Rivipansel (GMI-1070) in the Treatment of Vaso-Occlusive Crisis in Hospitalized Subjects With Sickle Cell Disease Completed · 51 cited
  5. Phase 4 Intranasal Fentanyl for Initial Treatment of a Vaso-occlusive Crisis Completed
  6. Phase 4 Actigraphy Improvement With Voxelotor (ActIVe) Study Completed
Show 28 more trials
  1. Phase 3 Silent Cerebral Infarct Transfusion Multi-Center Clinical Trial Completed
  2. Phase 2 Hydroxyurea Management in Kids: Intensive Versus Stable Dosage Strategies Completed
  3. Phase 2 Hydroxyurea and EPO in Sickle Cell Disease Completed
  4. Phase 2 Allogeneic Mixed Chimerism Stem Cell Transplant Using Campath for Hemoglobinopathies & Bone Marrow Failure Syndromes Completed
  5. Phase 2 L-Glutamine Therapy for Sickle Cell Anemia and Sickle ß0 Thalassemia Completed
  6. Phase 2 The Effect of Rivaroxaban in Sickle Cell Disease Completed
  7. Phase 2 Daily Vitamin D for Sickle-cell Respiratory Complications Completed
  8. Phase 2 Management of Severe Acute Malnutrition in SCD, in Northern Nigeria Completed
  9. Phase 2 Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Pediatric and Young Adult Patients With Sickle Cell Anemia Completed
  10. Phase 2 Effectiveness of Arginine as a Treatment for Sickle Cell Anemia Completed
  11. Phase 2 A Phase II Trial of Regadenoson in Sickle Cell Anemia Completed
  12. Phase 2 Losartan to Reverse Sickle Nephropathy Completed
  13. Phase 2 Antioxidant Therapy to Reduce Inflammation in Sickle Cell Disease Completed
  14. Phase 2 Prasugrel Versus Placebo in Adult Sickle Cell Disease Completed
  15. Phase 2 Nitric Oxide Inhalation to Treat Sickle Cell Pain Crises Completed
  16. Phase 2 Phase II Randomized Trial:Arginine Butyrate Plus Standard Local Therapy in Patients With Refractory Sickle Cell Ulcers Completed
  17. Phase 1 An Assessment of Prasugrel on Healthy Adults and Sickle Cell Adults Completed
  18. Phase 1 Red Cell Half Life Determination in Patients With and Without Sickle Cell Disease Completed
  19. Phase 1 A Study to Assess the Safety and Pharmacokinetics of HBI-002, an Oral Carbon Monoxide Therapeutic, in Healthy Volunteers Completed
  20. N/A Priapism in Boys and Men With Sickle Cell Disease - Demographics, Characteristics and Prevalence Completed
  21. N/A Evaluation of the AMICUS RBCx System in Sickle Cell Patients Completed
  22. N/A Decision Aid for Therapeutic Options In Sickle Cell Disease Completed
  23. N/A Shared-Decision Making for Hydroxyurea Completed
  24. N/A Microvascular Blood Flow in Sickle Cell Anemia Completed
  25. N/A Pediatric Hydroxyurea Phase III Clinical Trial (BABY HUG) Follow-up Observational Study II Protocol Completed
  26. N/A Long-Term Effects of Hydroxyurea in Children With Sickle Cell Anemia (The BABY HUG Follow-up Study) Completed
  27. N/A Examining Cognitive Function and Brain Abnormalities in Adults With Sickle Cell Disease Completed
  28. N/A Carbon Monoxide Measurement to Screen for Sickle Cell Disease Completed

Showing the 34 most-cited and recently-updated of 34 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Systematic review finds first FDA-approved CRISPR therapy and broader clinical trial exploration
Genetics & Precision Medicine Sys. Review
Systematic review finds first FDA-approved CRISPR therapy and broader clinical trial exploration First CRISPR gene therapy approved for blood disorders, with broader research underway
A systematic review of clinical trials registered at clinicaltrials.gov found the first CRISPR-Cas9 therapy obtained FDA approval in late 20…
The first CRISPR gene therapy is approved for sickle-cell anemia and β-thalassemia, with ongoing trials exploring its use for cancer and inf…
Frontiers Apr 3, 2026
Report examines use of recommended health care measures for sickle cell anemia complications in youth
Hematology
Report examines use of recommended health care measures for sickle cell anemia complications in youth Report examines use of preventive care for children with sickle cell anemia
A report describes the use of recommended health care measures to prevent complications of sickle cell anemia in children and adolescents in…
A new report looked at how children and adolescents with sickle cell anemia in the U.S.
CDC Apr 2, 2026

Research across Anemia

Related studies from across the Anemia family.

Roxadustat increases odds of vascular access thrombosis and all-cause mortality in patients with chronic kidney disease
Drug Pipeline Meta-analysis
Roxadustat increases odds of vascular access thrombosis and all-cause mortality in patients with chronic kidney disease Roxadustat Linked to Higher Risk of Blood Clots in Kidney Patients
This systematic review and meta-analysis of 11,418 adults with chronic kidney disease found that roxadustat is associated with higher odds o…
A review of over 11,000 patients suggests roxadustat may increase the risk of blood clots and death for those with chronic kidney disease.
Frontiers Jun 13, 2026
Vitamin D improves strength and reduces injuries in dancers, while iron lowers anemia prevalence
Nutrition & Obesity Medicine Meta-analysis
Vitamin D improves strength and reduces injuries in dancers, while iron lowers anemia prevalence Dancers take many supplements, but benefits are often unproven and risks remain unclear
This systematic review of dietary supplement and medication use in 654 female and 86 male professional and pre-professional dancers found vi…
Dancers use many supplements and painkillers, yet benefits are limited and potential health risks need more study before we can trust them.
Frontiers Jun 4, 2026
Systematic review reveals high prevalence of sickle cell disease across infants and youth in sub-Saharan Africa
Hematology Meta-analysis
Systematic review reveals high prevalence of sickle cell disease across infants and youth in sub-Saharan Africa Sickle cell disease affects nearly 2 percent of kids under 15 in sub-Saharan Africa
A comprehensive meta-analysis of 40 studies from 22 nations highlights the burden of sickle cell disease in sub-Saharan Africa. Prevalence r…
New analysis shows sickle cell disease is more common than thought in infants and children across sub-Saharan Africa, highlighting a critica…
Jun 1, 2026
Systematic review and meta-analysis finds roxadustat improves hemoglobin in peritoneal dialysis patients
Nephrology Meta-analysis
Systematic review and meta-analysis finds roxadustat improves hemoglobin in peritoneal dialysis patients Roxadustat Boosts Hemoglobin in Peritoneal Dialysis Patients
This systematic review and meta-analysis of 607 patients receiving peritoneal dialysis found that roxadustat significantly increased hemoglo…
A review of 607 patients on peritoneal dialysis finds roxadustat raises hemoglobin and iron levels while lowering hepcidin.
May 27, 2026
Narrative review of CRISPR-Cas9 and Fanzor gene therapies for sickle cell disease
Genetics & Precision Medicine Sys. Review
Narrative review of CRISPR-Cas9 and Fanzor gene therapies for sickle cell disease New CRISPR gene therapies for sickle cell disease face lingering technology limits
This narrative review synthesizes evidence on CRISPR-Cas9-based gene therapies and the Fanzor system for sickle cell disease. The authors no…
A review of CRISPR-Cas9 gene therapies for sickle cell disease notes that limitations in the technology still persist.
Frontiers May 26, 2026
Systematic review and meta-analysis of liposomal iron versus conventional iron in pediatric iron deficiency anemia
Pediatrics Meta-analysis
Systematic review and meta-analysis of liposomal iron versus conventional iron in pediatric iron deficiency anemia Liposomal iron improves blood counts and reduces side effects in children with anemia
This systematic review and meta-analysis evaluated liposomal iron versus conventional oral iron in 454 children with iron deficiency anemia …
A meta-analysis found liposomal iron raised hemoglobin more and caused fewer side effects than conventional iron in children.
May 25, 2026
Systematic review examines early erythropoiesis-stimulating agents for preterm infants across multiple clinical outcomes and safety endpoints
Neurology Sys. Review
Systematic review examines early erythropoiesis-stimulating agents for preterm infants across multiple clinical outcomes and safety endpoints Early blood boosters may lower severe brain injury risk in premature babies
A systematic review of 37 trials involving 6,724 preterm or low-birthweight infants found that early erythropoiesis-stimulating agents likel…
A review of 37 studies suggests early blood boosters might lower severe brain injury and severe gut illness in premature infants without rai…
Cochrane May 22, 2026
Systematic review and meta-analysis of erythropoiesis-stimulating agents in chronic heart failure and anaemia
Cardiology Meta-analysis
Systematic review and meta-analysis of erythropoiesis-stimulating agents in chronic heart failure and anaemia New drugs help heart failure patients stay out of the hospital
This systematic review and meta-analysis evaluated erythropoiesis-stimulating agents (ESAs) in adults with chronic heart failure and anaemia…
A new review shows specific drugs can keep heart failure patients out of the hospital while improving their daily energy and movement.
May 3, 2026
Eltrombopag addition alters clonal hematopoiesis dynamics in untreated severe aplastic anemia patients over 24 months
Drug Pipeline RCT
Eltrombopag addition alters clonal hematopoiesis dynamics in untreated severe aplastic anemia patients over 24 months Adding Eltrombopag helps severe anemia patients recover blood counts significantly faster
This Phase 3 randomized trial reviewed patient samples from 170 untreated patients with severe or very severe aplastic anemia receiving eltr…
Adding Eltrombopag helps severe anemia patients recover blood counts faster without increasing cancer risks but genetic changes rise over ti…
NEJM Evid Apr 28, 2026
Eltrombopag plus immunosuppression for severe aplastic anemia shows clonal evolution patterns
Pediatrics Phase II
Eltrombopag plus immunosuppression for severe aplastic anemia shows clonal evolution patterns Treatment for severe anemia reveals two paths to cancer risk
This phase 2 observational study followed 204 patients with severe aplastic anemia treated with immunosuppression plus eltrombopag for a med…
New research tracks cancer risks in severe anemia patients treated with standard therapy over five years
NEJM Evid Apr 28, 2026
Iron micronutrient powders reduce malaria-induced anaemia but not growth in young children
Nutrition & Obesity Medicine RCT
Iron micronutrient powders reduce malaria-induced anaemia but not growth in young children Iron powders reduce malaria-related anaemia in young children
This cluster-randomized trial in 1,806 Ghanaian children aged 6-35 months found that daily iron-containing micronutrient powders for five mo…
Daily iron-based micronutrient powders can lower the risk of malaria-induced anaemia in preschool children in Ghana.
medRxiv Apr 27, 2026
Pretreatment sTNFR1 and infection predict transplant-associated thrombotic microangiopathy in severe aplastic anemia
Allergy & Immunology Cohort
Pretreatment sTNFR1 and infection predict transplant-associated thrombotic microangiopathy in severe aplastic anemia A simple blood test may flag a deadly transplant complication before it starts
This prospective nested case–control study evaluated patients with severe aplastic anemia undergoing allogeneic hematopoietic stem cell tran…
A blood marker measured before transplant may flag a deadly complication in severe aplastic anemia patients.
Frontiers Apr 27, 2026